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Abstract
Rationale Alcohol-use disorders often occur together with anxiety disorders in humans which
may be partly due to common inherited genetic factors. Evidence suggests that the
endocannabinoid system (ECS) is a promising therapeutic target for the treatment of individuals
with anxiety and/or alcohol-use disorders.
Objectives The present study assessed the effects of a novel endocannabinoid uptake
inhibitor, LY2183240, on anxiety- and alcohol-seeking behaviors in a unique animal model that
may represent increased genetic risk to develop co-morbid anxiety and alcohol-use disorders in
humans. Mice selectively bred for high alcohol preference (HAP) show greater fear-potentiated
startle (FPS) than mice selectively bred for low alcohol preference (LAP). We examined the
effects of LY2183240 on the expression of FPS in HAP and LAP mice and on alcohol-induced
conditioned place preference (CPP) and limited-access alcohol drinking behavior in HAP mice.
Results Repeated administration of LY2183240 (30 mg/kg) reduced the expression of FPS in
HAP but not LAP mice when given prior to a second FPS test 48 hrs after fear conditioning.
Both the 10 and 30 mg/kg doses of LY2183240 enhanced the expression of alcohol-induced
CPP and this effect persisted in the absence of the drug. LY2183240 did not alter limitedaccess alcohol drinking behavior, unconditioned startle responding, or locomotor activity.
Conclusions These findings suggest that ECS modulation influences both conditioned fear
and conditioned alcohol reward behavior. LY2183240 may be an effective pharmacotherapy for
individuals with anxiety disorders, such as post-traumatic stress disorder, but may not be
appropriate for individuals with co-morbid anxiety and alcohol-use disorders.

Key Words: alcohol, cannabinoids, drinking, extinction, fear, preference
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Introduction
Alcohol abuse and alcoholism are common alcohol-use disorders that frequently occur
together with anxiety disorders (Kessler et al. 1997; Kushner et al. 1990), termed co-morbidity.
One hypothesis put forth to account for the co-morbid expression of alcohol-use and anxiety
disorders is that there are common factors, such as inherited genetic factors, that increase the
risk for developing both disorders. This hypothesis is supported by several studies in humans in
which alcoholism has been found to occur more frequently in individuals with a family history of
anxiety disorders (Maier et al., 1993; Munjack and Moss, 1981) and anxiety disorders occur
more frequently in individuals with a family history of alcoholism (Merikangas et al. 1985; 1998).
A growing body of evidence suggests that the endocannabinoid system (ECS) plays an
important role in regulating anxiety- and alcohol-related behaviors and may represent an
important drug target for the treatment of anxiety- and alcohol-use disorders. Genetic and
pharmacological studies support a prominent role for the ECS in regulating both anxiety(Pacher et al. 2006) and alcohol-related behaviors (Hungund and Basavarajappa, 2004). For
example, mice with genetic deletion (knockout) of cannabinoid (CB) 1 receptors exhibit more
anxiety-related behavior than wild-type mice in both unconditioned and conditioned anxiety
models (see reviews by Lafenêtre et al. 2007; Viveros et al. 2005). Direct agonists of the CB1
receptor and drugs that increase brain endocannabinoid (EC) levels (e.g., EC transport
inhibitors) produce anxiolysis in several models of unconditioned anxiety and facilitate extinction
of conditioned anxiety responses in fear conditioning models (Lutz, 2007; Pamplona et al. 2008;
Resstel et al. 2008).
With regard to alcohol-seeking behavior, genetic deletion and pharmacological blockade of
CB1 receptors reduces alcohol intake (e.g., Cippitelli et al. 2005; Colombo et al. 2007; Hansson
et al. 2007; Hungund et al. 2003), whereas enhancing ECS activity, either through CB1 receptor
activation (Gallate et al. 1999) or inhibition of EC breakdown (Hansson et al. 2007) often
increases alcohol intake in rodents. However, the EC uptake and metabolism inhibitor AM404
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has been shown to reduce alcohol intake in rats, an effect that was not mediated through CB
receptors (Cippitelli et al. 2007). There is also some evidence indicating that alterations in ECS
function may be a neurobiological mechanism that influences alcohol preference in rodents with
a genetic propensity toward high or low alcohol consumption (Cippitelli et al. 2005; Hansson et
al. 2007; Hungund and Basavarajappa, 2000). Finally, there are two published reports showing
that CB1 receptor knockout mice display weaker conditioned place preference (CPP) to alcohol
compared to wild-type controls (Houchi et al. 2005; Thanos et al. 2005), suggesting that CB1
receptors normally modulate the rewarding effects of alcohol.
Post-traumatic stress disorder (PTSD) is one anxiety disorder that has a particularly high
prevalence among people with alcohol-use disorders (Adams et al. 2006; Brady et al. 2000;
Breslau et al. 1997; Engel et al. 1999; Ikin et al. 2004; Kessler et al. 1995; 1996). The fearpotentiated startle (FPS) paradigm, where startle reactivity is enhanced by states of anxiety or
fear (Davis, 1990), may be a relevant model for PTSD because both humans and rodents show
FPS after exposure to trauma or stress-related stimuli (Grillon, 2002) and pharmaceutical drugs
used clinically to treat anxiety disorders reduce FPS (Hijzen et al. 1995). We have recently
shown that mice selectively bred for high alcohol preference (HAP) display greater FPS than
mice selectively bred for low alcohol preference (LAP) (Barrenha and Chester, 2007). These
findings suggest that common genes may influence the propensity to develop learned fearrelated behavior and alcohol drinking behavior in this mouse model and support the idea that
co-morbidity between alcohol-use and anxiety disorders such as PTSD in humans may have a
genetic basis (Maier et al. 1993; Merikangas et al. 1985; 1998; Munjack and Moss, 1981).
Selectively bred HAP mice may represent a unique genetic animal model to identify effective
pharmacotherapies for anxiety, alcohol-use disorders, or both.
The purpose of the present study was to assess the effects of a novel EC uptake
inhibitor, LY2183240, on FPS and alcohol-seeking behaviors in HAP mice. Little is known about
the behavioral effects or pharmacological actions of drugs that block the uptake and/or
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degradation of ECs. LY2183240, like the fatty acid amide hydrolase (FAAH) inhibitor URB597,
potently inhibits FAAH activity by carbamylation of the enzyme’s serine nucleophile. However,
unlike URB597, LY2183240 is not selective for FAAH as multiple other serine hydrolases are
inactivated by LY2183240 in vivo (Alexander and Cravatt, 2006). Alcohol-seeking behavior was
assessed using alcohol-induced CPP and a limited-access drinking paradigm. LY2183240 has
been shown to produce dose-dependent analgesia and associated increases in anandamide
(AEA) in rats (Moore et al. 2005) and inactivate FAAH in mice (Alexander and Cravatt, 2006).
However, this is the first study to examine the effects of LY2183240 on anxiety-related and
motivated behaviors in an animal model. Administration of LY2183240 was expected to reduce
FPS, based on similar findings in prior studies where activation of the ECS decreased anxietyrelated behavior. We also predicted that LY2183240 would enhance the expression of alcoholinduced CPP and increase alcohol drinking behavior based on the majority of reports indicating
that activation of the ECS enhances alcohol-seeking behavior.

Materials and Methods
Subjects
Subjects were adult male and female HAP mice from replicate lines 1 and 2 and LAP
mice from replicate line 1. HAP and LAP lines were produced by mass selection from outbred
HS/Ibg mice (Boulder, CO, USA) at the Indiana Alcohol Research Center (IARC) in Indianapolis,
IN, USA (Grahame et al. 1999). Subjects in the current study were alcohol naïve and were
generated at Purdue University from HAP and LAP breeders obtained from the IARC. Replicate
1 HAP mice were from the 34th and 37th generation and replicate 2 HAP mice were from the
27th, 29th, and 34th generation of selection for high alcohol preference. LAP mice were 7th and
8th generation offspring from generation 27 breeders maintained with relaxed selection. Mice
were between 62 and 103 days of age at the start of experimental procedures.
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Mice were housed in polycarbonate cages (29.2 x 19.0 x 12.7 cm) with aspen wood
shavings in groups of 2-4 per cage. For the drinking study (Experiment 3), mice were
acclimated to single housing for 7 days prior to the start of limited-access drinking. Ambient
temperature in the colony rooms ranged from 20.2-21.9ºC and animals had free-access to food
(Rodent Lab Diet 5001, Purina Mills Inc., St. Louis, MO, USA) and water throughout the
experiments. Experimental procedures were conducted during the light phase of a 12:12
light/dark cycle.
The experiments were carried out in accordance with the principles of laboratory animal
care and all procedures were approved by the Purdue Animal Care and Use Committee.

Drugs
For the place conditioning study, alcohol was diluted from a 95% (v/v) solution to a
concentration of 20% (v/v) with physiological saline (0.9%) and was administered
intraperitoneally (IP) in a dose of 2.0 grams per kilogram of body weight (g/kg) (0.06 g per 30 g
body weight) and in an injection volume of 12.6 ml/kg. For the drinking study, alcohol was
diluted from a 95% (v/v) solution to a concentration of 10% with tap water. LY2183240 was
dissolved in DMSO (did not exceed 3.75%) and suspended in 1.0%
carboxymethylcellulose/0.5% sodium lauryl sulfate/0.08% Tween 80 in distilled water and was
administered in doses of 10 and 30 mg/kg (0.3 and 0.9 mg/30 g body weight, respectively).
These doses of LY2183240 produced dose-dependent analgesia and associated increases in
AEA in rats (Moore et al. 2005) and inactivated FAAH in mice (Alexander and Cravatt, 2006).

Fear-potentiated Startle Apparatus
FPS was assessed using two dark, sound-attenuated Coulbourn Instruments (Allentown,
PA, USA) Animal Acoustic Startle System chambers, as previously described (Barrenha and
Chester, 2007). Startle stimuli consisted of 100 dB, 40 msec white noise bursts of varying
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intensities (frequency range: 20 Hz-20 kHz). Subjects’ startle responses were measured as the
amount of force in grams exerted against a weight-sensitive platform during the 200 msec after
the onset of each acoustic stimulus. The force measurement does not include the subject’s
bodyweight, which removes any variation in startle response magnitude that may be accounted
for by individual differences. A ventilating fan provided continuous 70-71 dB background noise.

Place Conditioning Apparatus
The place conditioning apparatus consisted of 8 identical open-top boxes enclosed in
separate ventilated sound- and light-attenuating chambers, as previously described (Chester
and Coon, 2010). The floor of each box consisted of interchangeable halves with distinct floor
textures (grid or hole). Locomotor activity and side position (left or right) for each mouse was
continuously monitored by the Hamilton-Kinder MotorMonitor program (Model HMM100, San
Diego, CA, USA).

Blood Alcohol Concentration (BAC) Analysis
For the alcohol drinking study, approximately 0.05 ml of blood was collected from the
submandibular vein into heparinized capillary tubes (Fisher Scientific, Pittsburgh, PA, USA).
Blood samples were placed on ice, immediately centrifuged at 12,000 rpm, and plasma was
extracted and frozen at –80 C until analyzed for BAC using an AM1 Analyzer (Analox
Instruments, Lunenburg, MA, USA).

Study Procedures
Experiment 1: Effects of LY2183240 on the Expression of FPS
Experiment 1 consisted of three separate experiments (1a-1c). The purpose of
Experiment 1a (n=66; 37 HAP male, 29 HAP female) was to assess the effects of LY2183240
on the expression of FPS in HAP mice and was conducted in two matched replications.
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Experiment 1b (n=48; 24 HAP male, 24 HAP female) was conducted to replicate the findings in
Experiment 1a because average FPS responses in the vehicle-treated group in Experiment 1a
were lower than that previously reported in HAP mice (Barrenha and Chester, 2007). The
purpose of Experiment 1c (n=31; 14 LAP male, 17 LAP female) was to assess the effects of
LY2183240 on FPS in LAP mice.
Mice received 60-min conditioning sessions and 55-min FPS test sessions, as previously
described (Barrenha and Chester, 2007). Briefly, the conditioning session began with 10 trials
of 100 dB (40 msec) startle stimuli separated by a 2-min inter-trial interval (ITI) followed by
twenty conditioning trials. Each conditioning trial consisted of a 30-sec, 7 W light stimulus
paired with a 0.5-sec, 0.8 mA footshock. The FPS test session consisted of 36 total trials
separated by a 2-min ITI and were presented randomly throughout the test session to avoid
habituation to any single trial type. Twelve of the trials were blank (no stimuli), 12 were noise
alone (100 dB, 40 msec), and 12 were light (7 W, 30 sec) + noise (100dB, 40 msec). On light +
noise trials, the noise stimulus was presented immediately after the light stimulus ended. Mice
were tested for FPS twice: 24 and 48 hrs after the conditioning session. Mice received an IP
injection of either vehicle, 10 or 30 mg/kg LY2183240 30 min before each FPS test.

Experiment 2: Effects of LY2183240 on the Expression of Alcohol-induced CPP
The place conditioning study involved one pre-conditioning preference test, eight
conditioning sessions, and three post-conditioning preference tests. Conditioning and
preference tests were conducted on consecutive days except that a 2-day break separated the
first four and second four conditioning sessions.
HAP mice (n=90; 42 HAP male, 48 HAP female) were exposed to a Pavlovian
differential place conditioning procedure, as previously described (e.g., Chester and Coon,
2010). On alternating days during conditioning, mice in the grid+ subgroup received an IP
injection of alcohol (2.0 g/kg) immediately before a 5-min conditioning session on the grid floor.
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These mice received saline before exposure to the hole floor on intervening days. Conversely,
mice in the hole+ subgroup received alcohol paired with the hole floor and saline paired with the
grid floor. Assignment of mice to experimental groups and conditioning subgroups was
counterbalanced by litter of origin, order of exposure to alcohol or saline, order of exposure to
the floor textures (grid or hole), floor position (left or right side of the box) during preference
tests, and apparatus enclosure.
For the pre-conditioning preference test, all mice received a saline injection immediately
before being placed in the apparatus on a half grid/half hole floor for 60 min. Three postconditioning preference tests were administered 24, 48, and 72 hrs after the final conditioning
session. Mice received an IP injection of either vehicle, 10 or 30 mg/kg LY2183240 30 min
before the first two preference tests and a saline injection 30 min prior to the third preference
test to assess whether any effects of LY2183240 on alcohol-induced CPP would be maintained
in the absence of the drug.

Experiment 3: Effects of LY2183240 on Limited-access Alcohol Drinking
HAP mice (n=43; 23 HAP male, 20 HAP female) were exposed to a 2-hr limited-access
drinking procedure. Two days before the limited-access acquisition phase began mice were
weighed and given IP saline injections to habituate them to handling and injection procedures.
On days 1-6, standard water bottles were replaced for 2 hrs with two 25 ml graduated cylinders
fitted with stainless steel sipper tubes. One tube contained tap water and the other contained a
10% v/v alcohol solution. On these days mice were weighed 30 min before the start of the 2-hr
drinking session but no injections were given. On days 7-8, mice were weighed and received
saline injections 30 min before the start of the 2-hr drinking session. Based on the average
alcohol intake on these 2 days, mice were assigned to drug treatment groups in a
counterbalanced fashion. On the drug testing days (days 9-10), mice received an injection of
vehicle, 10 or 30 mg/kg LY2183240 30 min prior to the start of the 2-hr drinking session.
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Immediately after the final fluid intake reading on the second drug testing day, a blood sample
was taken from each mouse to assess BAC in all drug treatment groups. Fluid intake was read
to the nearest 0.5 ml once at 30 min after the start of, and again at the end of, the 2-hr drinking
sessions. Left/right bottle positions were alternated daily to avoid a possible positional
preference. The 2-hr drinking sessions occurred during the last 2 hrs of the light phase of the
12:12 light/dark cycle.

Statistical Analyses
Acoustic startle responses for each mouse on the 12 noise-alone and light+noise trials
were averaged. FPS was analyzed using a proportional change score, termed % FPS,
calculated with the following formula: [((average startle amplitude on light+noise trials - average
startle amplitude on noise-alone trials)/average startle amplitude on noise-alone trials) x 100].
The % FPS measure adjusts for individual and group differences in startle reactivity and is an
accurate and sensitive measure of FPS (Risbrough et al. 2003; Walker and Davis, 2002). Three
mice were removed from Experiment 1 because their startle responses across all startle trials
(including pre-training startle trials) did not reach the minimum startle response criterion of 11
grams of force.
Thirty-one HAP mice (15 male and 16 female) were excluded from Experiment 3 due to
inconsistent alcohol intake behavior during the 2-hr limited-access acquisition phase. Mice
were excluded if they met either of the following two criteria: 1) no alcohol intake for 2
consecutive days after the initial 3 days of limited-access exposure, or 2) no alcohol intake on
either of the baseline limited-access days (where limited-access was preceded by saline
injections). Data points lost because of fluid spillage or that were deemed to be outliers were
replaced with an average intake value, as previously described (Chester et al., 2008). There
were 2 missing values and 3 valid outliers during the acquisition phase only.

11
Data were analyzed using analysis of variance (ANOVA) with the significance level set
at p<0.05. Between-group factors included Dose Group, Sex, Conditioning Subgroup (grid+ or
hole+) and Study Replication (Experiment 1) and within-group factors included Test Day, Floor
Type (grid or hole), Conditioning Session Type (alcohol or saline), Trial, Block (2-day drinking
averages), or Time, where applicable. Significant interactions were followed using lower-order
one-way ANOVAs and Tukey’s multiple comparison tests (Keppel, 1991).

Results
Experiment 1: Effects of LY2183240 on the Expression of FPS
Figure 1 shows data from the first and second FPS test in HAP mice. During the first
FPS test, there were no significant effects of LY2183240 on the expression of FPS. However,
during the second FPS test, the 30 mg/kg dose of LY2183240 significantly reduced the
expression of FPS.
Initial analysis of the data in HAP mice from Experiments 1a and 1b included Study
Replication as a factor in the repeated-measures ANOVA (Study Replication x Dose Group x
Sex x Test Day). This analysis yielded a Dose Group x Test Day interaction [F(2,96)=3.8,
p<0.05] but no interactions with Study Replication. Follow-up one-way ANOVAs of Dose Group
on each test day yielded a significant main effect of Dose Group on test day 2 only
[F(2,111)=6.3, p<0.01]. Tukey’s post-hoc analyses of % FPS revealed significantly lower %
FPS in mice treated with 30 mg/kg LY2183240 compared to the vehicle (p<0.01) and to the 10
mg/kg (p<0.05) dose groups.
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Analysis of data on noise-alone trials in HAP mice (Study Replication x Dose Group x
Sex x Test Day ANOVA) indicated a Dose Group x Test Day interaction [F(2,96)=4.2, p<0.05]
but follow-up one-way ANOVAs of Dose Group within each Test Day yielded no significant
differences (data not shown). These data indicate that the effect of LY2183240 on % FPS in
HAP mice is not due to alterations in unconditioned startle responses.
Figure 2 shows data from the first and second FPS test in LAP mice (Experiment 1c).
LY2183240 did not alter % FPS or unconditioned startle responses. Analysis of % FPS and
noise-alone startle data (Dose Group x Sex x Test Day ANOVAs) showed only main effects of
Test Day for % FPS [F(1,25)=6.2, p<0.05; test 2 > test 1] and for noise-alone startle responses
[F(1,25)=10.0, p<0.01; test 1>test 2].
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Experiment 2: Effects of LY2183240 on the Expression of Alcohol-induced CPP
Pre-test
Mice spent on average more time on the grid floor (32.4±0.8 sec/min) vs. the hole floor
(27.6±0.8 sec/min) during the 60-min pre-test. Analysis of the raw time spent on the grid or hole
floor [Dose Group x Sex x Floor Type x Time (first 30 and last 30 min) ANOVA] yielded a main
effect of Floor Type [F(1,84)=8.0, p<0.01; grid > hole]. Data for all mice were transformed to
time on CS+ floor and this variable was subjected to a Dose Group x Sex x Conditioning
Subgroup x Time ANOVA which revealed a main effects of Time [F(1,78)=7.7, p<0.01] and
Conditioning Subgroup [F(1,78) =6.3, p=0.01] due to mice in the hole+ subgroup spending less
time on their CS+ floor (26.3±1.1 sec/min) then mice in the grid+ group (30.6±1.2 sec/min).
Importantly, however, there were no main effects of Drug Group or interactions with this factor
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indicating that time spent on the CS+ floor during both the first 30 and last 30 min of the pre-test
was similar in all dose groups prior to the start of conditioning. Mean (±SEM) activity counts
during the pre-test were significantly higher during the first 30 min (77.6±1.2 counts/min) than
the last 30 min of the pre-test (52.7±1.8 counts/min) [F(1,89)=226.8, p<0.01].

Conditioning Trial Activity
Figure 3 depicts mean (±SEM) activity counts during CS+ and CS- conditioning sessions
across conditioning trials 1-4, collapsed across sex because no main effect or three way
interaction with this factor was found. Alcohol produced locomotor activation on CS+ trials
compared to CS- trials. In addition, alcohol-stimulated locomotor activity increased across trials
indicating that sensitization to the locomotor activating effects of alcohol occurred. Overall
analysis of the data (Sex x Conditioning Session Type x Trial) yielded main effects of
Conditioning Session Type [F(1,88)=958.7, p<0.001] and Trial [F(3,264)=7.0, p<0.001], and Sex
x Conditioning Session Type [F(1,88)=22.1, p<0.01], Sex x Trial [F(3,264)=3.3, p<0.05] and
Conditioning Session Type x Trial [F(3,264)=28.9, p<0.001] interactions. Follow-up one-way
ANOVAs of Trial within each conditioning session type indicated an increase in activity across
CS+ conditioning sessions [F(3,267)=2.9, p<0.05] and a decrease in activity across CSconditioning sessions [F(3,267)=75.7, p<0.001].
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Conditioning Trial
Post-tests
Table 1 shows the mean (±SEM) time on the CS+ floor (sec/min) in each LY2183240 dose
group during the first 30 min of the pre-test and post-tests. Analysis of raw post-test scores
without reference to pre-test scores did not yield a significant main effect of or interaction with
Dose Group. Evidence for place conditioning was further assessed by calculating within-subject
difference scores that reflect change in the amount of time spent on the CS+ floor during the
post-test relative to the amount of time spent on the CS+ floor during the pre-test. Figure 4
shows place conditioning data for each LY2183240 dose group. Each preference test is
depicted separately even though preference remained relatively constant across the three tests,
as supported by the lack of statistical interactions with the repeated measures Test Day factor
(see below).
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Table 1. Average time (sec/min) spent on the alcohol-paired (CS+) floor in HAP mice
First 30 min

Last 30 min

Pretest
Test 1
Test 2
Test 3
Pretest
Test 1
Test 2
Test 3
___________________________________________________________________________________
Vehicle (n=30)

30.8±1.3 40.5±2.0 36.5±2.1 36.7±2.2

29.6±2.2 38.2±2.6 35.3±3.1 35.9±2.9

10 mg/kg (n=30)

29.4±0.9 43.8±1.6 37.7±2.2 38.1±1.4

26.2±2.1 41.9±2.4 40.6±2.6 38.8±2.7

30 mg/kg (n=30) 29.1±1.1 41.8±2.2 36.7±2.4 39.9±1.9
25.8±2.1 43.1±2.5 39.9±2.9 39.3±2.9
___________________________________________________________________________________

Alcohol-induced CPP was increased during the last 30 min of the preference tests in both
the 10 and 30 mg/kg LY2183240 dose groups. Initial analysis of the data was conducted using
a five-way ANOVA [Dose Group x Sex x Conditioning Subgroup x Test Day x Time (first 30 min
and last 30 min)] with repeated measures on the Test Day factor to determine if preference
changed over the course of repeated testing in the presence and absence of LY2183240. This
analysis revealed main effects of Test Day [F(2,156)=7.6, p<0.01] and Time [F(1,78)=5.5,
p<0.05], a Conditioning Subgroup x Test Day interaction [F(2,156)=6.2, p<0.01], and a Dose
Group x Conditioning Subgroup x Test Day x Time interaction very close to significance [F(4,
156)= 2.4, p=0.055]. Follow up ANOVAs (Dose Group x Conditioning Subgroup x Test Day) of
the four-way interaction were conducted separately for the first 30 and last 30 min of the
preference test. For the first 30 min analysis, the ANOVA showed a main effect of Test Day
[F(2,168)=16.3, p<0.001] and a Conditioning Subgroup x Test Day interaction [F(2,168)=8.3,
p<0.001]. For the last 30 min analysis, the ANOVA showed a main effect of Dose Group
[F(2,84)=3.2, p<0.05] and a Conditioning Subgroup x Test Day interaction F(2,168)=3.8, p<0.05.
As can be seen in Figure 4, the main effect of Dose Group can be accounted for by an increase
in alcohol-induced CPP in both the 10 and 30 mg/kg groups compared to the vehicle group
during each of the three preference tests. Follow up analyses of Dose Group using Tukey’s
multiple comparison test indicated that the 30 mg/kg dose of LY2183240 produced a greater
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enhancement of alcohol induced CPP (vehicle vs. 10 mg/kg groups: p=0.098; vehicle vs. 30
mg/kg groups: p=0.062).

Figure 4
Preference Test 1: LY2183240 pretreatment

Mean (±SEM) sec/min on alcohol-paired floor
(post-test - pretest difference score)
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Activity During Post-tests
Test activity data were analyzed using a three-way ANOVA (Dose Group x Sex x Test Day x
Time). The analysis yielded main effects of Test Day [F(2,168)=6.6, p<0.01] and Time
[F(1,84)=466.3, p<0.001] and Dose Group x Time [F(2,84)=4.4, p<0.05] and Test Day x Time
[F(2,168)=3.2, p<0.05] interactions. The Dose Group x Time interaction was further examined
with one-way ANOVAs of Dose Group for the first and last 30 min of the test sessions
(collapsed across the three tests) but these analyses showed no significant effect of Dose
Group. Mean (±SEM) activity counts during the first and last 30 min of the preference tests,
respectively, were 64.3±1.8 and 43.2±1.9 for test 1, 64.0±1.7 and 38.8±2.1 for test 2, and
60.6±1.5 and 37.2±1.9 for test 3. These analyses indicate that the observed effects of
LY2183240 on the expression of CPP are not related to drug-induced changes in locomotor
activity during test sessions.

Experiment 3: Effects of LY2183240 on Limited-access Alcohol Drinking
On the first day of the 2-hr limited-access procedure, mean (±SEM) body weights were
26.6±0.4 g for male and 22.6±0.5 g for female mice. A one-way ANOVA yielded a main effect
of Sex [F(1,41)=41.2, p<0.01; male>female].
Figure 5 shows alcohol (g/kg) and total fluid (ml/kg) intake during the acquisition phase
averaged across 2-day blocks. Sex x Block ANOVAs indicated that alcohol intake and total fluid
intake did not significantly change during the acquisition phase.
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Figure 5
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Figure 6a shows alcohol (g/kg) intake during the 2 hrs of limited-access on both drug
days. LY2183240 did not significantly alter alcohol intake (g/kg) on either drug testing day. A
repeated measures ANOVA (Dose Group x Sex x Test Day) yielded no effects of LY2183240 on
alcohol intake during the 2 hrs of limited-access, but a significant Dose Group x Test Day
interaction [F(2,37)=3.0, p<0.05] was found during the first 30 min of the 2-hr drinking session.
Follow up ANOVAs of Dose Group within each test day yielded no significant effects (data not
shown).
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Pearson’s product moment correlation indicated that total alcohol intake (g/kg) during the
final drinking session was significantly correlated with BAC (r2=0.77, p<0.01). LY2183240 did
not affect alcohol metabolism in HAP mice based on the ANOVA (Dose Group x Sex) of BAC,
taken at the end of the final 2-hr drinking session, that yielded no significant main effects or
interactions.
Figure 6b shows total fluid (ml/kg) intake during the 2-hr limited-access sessions on both
drug days. LY2183240 had no effect on total fluid intake, which was stable across drug testing
days. Repeated measures ANOVA (Dose Group x Sex x Test Day) on total fluid intake after
both the 30 min and 2-hr time points yielded only a Dose Group x Sex x Test Day interaction
[F(2,37)=3.6,p<0.01] for total fluid (ml/kg) intake during the first 30 min of limited-access but
follow-up lower order ANOVAs yielded no significant effects.

Discussion
The goal of the present study was to assess the effects of a novel EC uptake inhibitor,
LY2183240, on anxiety- and alcohol-seeking behaviors in selectively bred high alcohol
preferring mice. LY2183240 produced anxiolytic-like effects using the FPS procedure and also
increased alcohol-seeking behavior in the CPP procedure. There were no significant effects of
LY2183240 on alcohol drinking behavior. The effects of LY2183240 appear to be selective for
conditioned behaviors because LY2183240 did not alter unconditioned startle responses or
general locomotor activity. Furthermore, LY2183240 did not alter the expression of FPS in LAP
mice suggesting that the anxiolytic effect of LY2183240 may be selective for mice with a genetic
propensity toward greater anxiety-related behavior. These findings suggest that LY2183240
may influence memory-related processes that regulate the expression of conditioned fear and
conditioned alcohol reward behavior in HAP mice.
It is well-established that the ECS plays an important role in regulating memory-related
processes such as extinction and reconsolidation (see reviews by Diergaarde et al. 2008; Lutz,
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2007). Extinction is a process in which new learning is thought to inhibit the expression of a
conditioned response (Konorski, 1967; Rescorla, 2001). On the other hand, reconsolidation of a
memory may act to stabilize a conditioned response (Przybyslawski and Sara, 1997; Rudy et al.
2006). Although the conditions under which one process may predominate over the other are
still a matter of debate, it is generally thought that a brief re-exposure to conditioned cues leads
to reconsolidation whereas a longer re-exposure to the conditioned cues leads to extinction
(Pedreira and Maldonado, 2003). It has also been suggested that the two processes may
compete depending on the behavioral testing conditions (see review by Eisenhardt and Menzel,
2007). The current studies were not specifically designed to differentiate between effects of
LY2183240 on reconsolidation vs. extinction; however, our data provide some clues as to how
LY2183240 may affect these memory-related processes (discussed below).
Results of several prior studies have shown that administration of AEA transport
inhibitors (Bitencourt et al. 2008; Chhatwal et al. 2005; Pamplona et al. 2008; Resstel et al.
2008) or AEA itself (Resstel et al. 2008) facilitates the extinction of learned fear responses in
models of fear conditioning. Consistent with these prior reports, we found that the higher dose
of LY2183240 (30 mg/kg) significantly reduced the expression of FPS, but only after a second
FPS test. This result is comparable to that reported by Chhatwal et al. (2005) who found similar
effects of the EC uptake inhibitor, AM404, on conditioned fear using the FPS model. In that
study, administration of AM404 prior to extinction training (re-exposure to conditioned light cues)
reduced the subsequent expression of FPS but had no effect on FPS when extinction training
was omitted. This result is analogous to that seen in the current study where LY2183240 did
not alter FPS expression during the first test. Thus, the first FPS test may have served as an
extinction session that led to the nearly complete elimination of FPS seen during the second
FPS test in the 30 mg/kg LY2183240 dose group. We interpret these data to suggest that
sustained activation of the ECS via LY2183240 during repeated exposure to conditioned fear
stimuli may be necessary to facilitate the extinction of learned fear responses. However, this
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interpretation should be taken with caution as the FPS procedure used here was not specifically
designed to assess extinction. Additional studies will also be important to examine whether the
effects of LY2183240 on FPS expression persist in the absence of the drug.
It has previously been reported that alcohol produces weaker CPP in CB1 receptor
knockout mice compared to their wild-type controls (Houchi et al. 2005; Thanos et al. 2005),
indicating that CB1 receptors modulate the rewarding effects of alcohol and the acquisition of
alcohol-induced CPP. The present data are the first to show that pharmacological modulation of
the ECS influences the expression of alcohol-induced CPP in mice. Consistent with our
hypothesis, LY2183240 enhanced the expression of alcohol-induced CPP. This result suggests
that LY2183240 may increase the incentive salience of conditioned floor cues associated with
alcohol reward and facilitate approach behavior during the place preference test. The effect of
LY2183240 on CPP expression was moderate in size and was most prominent during the last
30 min of the preference tests. The fact that this effect emerged during the last half of the
preference tests and was maintained to the same degree on the third preference test in the
absence of the drug, suggests that exposure to the pharmacological effects of LY2183240
together with alcohol conditioned cues may strengthen the alcohol reward-related memory.
Such an interpretation could be consistent with a reconsolidation hypothesis if one considers
that the first 30 min of the preference test might be analogous to a relatively brief period of reexposure to the conditioned cues, as has been suggested for reconsolidation to occur (e.g.,
Przybyslawski and Sara, 1997). In this case, exposure to the conditioned cues at the start of
the preference test, along with LY2183240 pretreatment, may have served to “reactivate” and
subsequently strengthen the alcohol reward memory. There is emerging evidence that the ECS
may influence memory reconsolidation (see review by Diergaarde et al. 2008), including drug
reward-related memories. For example, Yu and colleagues (2009) recently reported that the
CB1 receptor antagonist SR141716A (rimonabant) interfered with the reconsolidation of
methamphetamine-induced CPP. Of course, this idea remains speculative in the absence of a
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defined procedure to specifically test memory reconsolidation in the present study. An
alternative interpretation of the CPP data is that LY2183240 reduced a conditioned aversion to
alcohol which increased the magnitude of alcohol-induced CPP. This idea is relevant to the
extent that expression of the overall magnitude of the CPP may be moderated to some degree
by conditioned aversive motivational effects of alcohol in addition to rewarding effects of alcohol
(see Cunningham et al., 2003 for an experimental analysis and discussion of this issue). Future
place or taste aversion studies could be conducted to test whether LY2183240 alters the
expression of conditioned aversion to alcohol.
Taken together, results of the FPS and CPP studies suggest that ECS activation by
LY2183240 seems to influence the expression of learned behaviors, but the direction of the
effect depends on the type of learning involved. LY2183240 attenuated the conditioned
response produced by an aversive shock stimulus and enhanced the conditioned response
produced by a rewarding alcohol stimulus, perhaps through effects on extinction or memory
reconsolidation. The apparent diversity of LY2183240’s effects on aversive and appetitive
behaviors is somewhat akin to reported findings in the literature in which ECS drugs have been
studied. For example, rimonabant disrupted extinction of aversive conditioned responses in
fear-conditioning and passive avoidance tasks but had no effect on learned responses in an
appetitively motivated food task (Niyuhire et al. 2007). Rimonabant has also been shown to
interfere with extinction learning in an aversive but not appetitive Barnes maze conditioning
procedure (Harloe et al. 2008). In addition, Manwell et al. (2009) reported that the EC uptake
inhibitor, URB597, facilitated extinction, whereas rimonabant inhibited extinction, of conditioned
place aversion to naloxone-precipitated morphine withdrawal but neither drug affected
morphine-induced CPP.
The ECS has very diverse roles in the regulation of neuronal function and behavior (see
review by Kano et al. 2009). It is likely that the different effects of EC drugs on aversive vs.
appetitive conditioned behavior seen in the present study and in prior reports are largely
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attributable to differential modulation of EC function in discrete brain regions involved in
memory, anxiety, and drug reward. For example, the amygdala is a brain structure critically
involved in auditory fear conditioned behavior such as FPS (Davis, 2006), and tone
presentations during conditioned fear extinction trials are associated with elevated levels of ECs
in the amygdala but not in other brain regions such as the prefrontal cortex (PFC) (Marsicano et
al. 2002). ECs regulate neural signaling in reward-related brain regions such as the ventral
tegmental area and nucleus accumbens (see review by López-Moreno et al. 2008), areas that
have been specifically implicated in the expression of alcohol-induced CPP in mice (Bechtholt
and Cunningham, 2005; Gremel and Cunningham, 2008). Thus, systemic administration of
LY2183240 may result in different neurochemical and behavioral effects depending on the basal
or activity-dependent levels of ECs and CB receptor distribution in these various brain regions.
Inactivation of the ECS by genetic deletion and pharmacological blockade of CB1
receptors has been shown to reduce alcohol intake (e.g., Cippitelli et al. 2005; Colombo et al.
2007; Hansson et al. 2007; Hungund et al. 2003), while stimulating the ECS by direct CB1
activation increases alcohol seeking behavior assessed via operant self-administration (Gallate
et al. 1999; Hansson et al. 2007) and home-cage, 24-hr, free-access procedures (Colombo et
al. 2002). In theory, one would predict that EC uptake inhibitors should have similar effects as
CB1 receptor direct agonists because enhancing synaptic EC levels should result in greater
CB1 receptor activation. However, EC uptake inhibitors have been reported to have
inconsistent effects on alcohol intake behavior that may be related, in part, to differences in drug
mechanism of action, drinking procedures, strain, or species. For example, URB597 has been
shown to both increase (Hansson et al. 2007) and have no effect (Cippitelli et al. 2008) on
operant self-administration in Wistar rats. In studies using home-cage drinking procedures,
URB597 increased drinking during 8-hr and 24-hr free-access periods in C57BL/6J mice (Vinod
et al. 2008) and in mice with a 129/SvJ/C57Bl/6J genetic background (Blednov et al. 2007),
respectively, but did not alter drinking during a 1-hr alcohol access period in selectively bred
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Marchigian Sardinian alcohol-preferring (msP) rats (Cippitelli et al. 2008). Another EC uptake
inhibitor, AM404, reduced operant responding for alcohol in rats, an effect that was not
mediated through CB1 or CB2 receptors (Cippitelli et al. 2007). These findings suggest that EC
uptake inhibitors have unique, yet still poorly understood, pharmacological properties and may
interact with the ECS or other neurotransmitter systems in diverse ways to affect behavior.
In contrast to our hypothesis, LY2183240 in the current study did not alter alcohol intake
in a 2-hr limited access drinking procedure in HAP mice. This result is consistent with those
reported by Cippitelli and colleagues (2008) where URB597 had no effect on alcohol intake in
alcohol preferring msP rats during a 1-hr limited access drinking paradigm. It should be noted
that several studies have reported altered ECS function in alcohol-naïve rodents with a genetic
propensity toward high alcohol preference when compared to their low-alcohol-preferring
counterparts (Cippitelli et al. 2005; Hansson et al. 2007; Hungund and Basavarajappa, 2000).
For example, Hansson and colleagues (2007) found decreased CB1 receptor expression in the
PFC, as well as decreased FAAH expression and higher levels of ECs [1- arachidonoylglycerol
(AG) and 2-AG, but not AEA], in the alcohol-preferring Alko Alcohol (AA) rat line compared to
the nonpreferring Alko Non-Alcohol (ANA) rat line. Thus, altered sensitivity to the effects of EC
uptake/FAAH inhibitors in animals that differ in genetic predisposition toward alcohol drinking
may be an important factor that could explain absent or discrepant effects of EC drugs on
behavior. We are currently examining whether ECS function differs in selectively bred HAP vs.
LAP mice.
CPP is thought to be a useful model for understanding certain learning and memory
processes and to investigate the role of environmental cues in influencing craving, relapse, and
alcohol-seeking behavior, whereas oral alcohol intake procedures assess the primary
reinforcing effects of alcohol via consummatory behavior models (Cunningham et al. 2000).
Assessments of the relation between alcohol drinking behavior and alcohol-induced CPP using
pharmacological and genetic manipulations suggest that these two behavioral models seem to
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tap into similar alcohol-reward related mechanisms, at least in mice (see review by Green and
Grahame, 2008). However, there are numerous examples in the literature that also highlight a
dissociation between alcohol-reward related behavior as measured in CPP (e.g., Chester et al.
1998; Cunningham et al. 1992; Dickinson et al. 2003; Risinger et al. 1992a; 1992b) vs. oral
alcohol intake procedures (e.g., Hodge et al. 1997; Kosobud et al. 1988; Ng and George, 1994;
Samson et al. 1987). The finding that LY2183240 increased the expression of alcohol-induced
CPP but did not alter alcohol drinking behavior in the current study provides further support for
the idea that these two alcohol-reward related behaviors are regulated by different
neurobiological mechanisms and that LY2183240 may modulate memory mechanisms
important for the expression of conditioned but not unconditioned alcohol reward behavior.
Future studies should examine the effects of CB1 receptor antagonists in combination
with LY2183240 to explore the extent to which the effects of LY2183240 may be mediated
through CB1 receptor activation. While the behavioral effects of LY2183240 are likely mediated
through actions at CB receptors in the brain, it is also possible that other receptors activated by
the ECs may be involved. Transient receptor potential V1 receptors are activated by AEA and
are thought to primarily function in pain and inflammatory responses although a role in mood
has been suggested (De Petrocellis and Di Marzo, 2009). The ECs are also agonists at nuclear
peroxisome proliferator-activated receptors (PPARs). Physiological actions associated with EC
action at PPARs include regulation of metabolic functions, pain, and inflammatory processes
making it unlikely that the effects observed in the present study are associated with activity at
the PPARs (O'Sullivan, 2007). Also, the use of a monoacylglycerol lipase inhibitor to selectively
elevate 2-AG vs. AEA would be useful to further characterize the pharmacological basis for the
behavioral effects of LY2183240. Finally, it should be noted that the ECs represent a diverse
set of lipid signaling molecules and LY2183240 inactivates other serine hydrolases besides
FAAH (Alexander and Cravatt, 2006); thus, other fatty acid amides or esters besides AEA or 2AG may mediate the behavioral effects seen in the present study.
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In conclusion, selectively bred HAP mice are a unique animal model that represents
increased genetic risk to develop alcoholism and co-morbid PTSD in humans and provides a
useful tool to explore pharmacological interventions for these co-morbid disorders. Here, we
provide original findings in the HAP model that add to a growing body of literature centered on
the identification of new therapies for co-morbid disorders. Results of the present study showed
that the novel EC uptake inhibitor, LY2183240, decreased FPS and increased alcohol-induced
CPP in HAP mice. These data suggest that drugs such as LY2183240 that target the EC
uptake mechanism may be particularly effective in the treatment of anxiety disorders such as
PTSD, a disorder which is thought to involve impaired extinction of aversive memories.
However, cautious interpretation of the present data suggests that LY2183240 or similar drugs
may not be a useful therapy for individuals with independent or co-morbid alcohol-use disorders.
This work may ultimately help to identify novel drug treatments to reduce both anxiety and
alcohol consumption in people with co-morbid disorders and these pharmacological treatment
strategies may prove to be particularly effective in people who are at increased genetic risk for
both alcoholism and PTSD.
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Figure Legends
Figure 1. Mean (±SEM) %FPS in male and female HAP mice in each LY2183240 dose group
during the first (Test 1) and second (Test 2) FPS test. Mice received IP injections of either drug
(10 mg/kg or 30 mg/kg) or vehicle 30 min before each FPS test, which were given 24 hrs apart.
*Indicates p<0.05 (10 mg/kg vs. 30 mg/kg); **indicates p<0.01 (0 vs. 30 mg/kg).

Figure 2. Mean (±SEM) %FPS in male and female LAP mice for each LY2183240 dose group
during the first (Test 1) and second (Test 2) FPS test. Mice received IP injections of either drug
(10 mg/kg or 30 mg/kg) or vehicle 30 min before each FPS test, which were given 24 hrs apart.

Figure 3. Mean (±SEM) activity counts per minute for male and female HAP mice during CS+
and CS- conditioning trials.

Figure 4. Mean (±SEM) sec per minute (sec/min) on alcohol-paired floor (post-test – pre-test
difference score) in male and female HAP mice in each LY2183240 dose group during the first
and last 30 min of each of the three preference tests. Mice received IP injections of either drug
(10 mg/kg or 30 mg/kg) or vehicle 30 min before the first two preference tests (top and middle
panels) and saline injections 30 min before the drug-free preference test (bottom panel).
*Indicates main effect of Dose Group collapsed across preference tests (p<0.05).

Figure 5. Mean (±SEM) alcohol (left y-axis; g/kg) and total fluid (right y-axis; ml/kg) intake in
HAP mice averaged across 2-day blocks during the 8 days of the alcohol acquisition phase. IP
saline injections were administered 30 min prior to the 2-hr limited-access sessions on the final
two days of the acquisition phase (block 4).
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Figure 6. Mean (±SEM) alcohol (g/kg; panel a) and total fluid (ml/kg; panel b) intake in HAP
mice within each LY2183240 dose group during the 2-hr limited access session on the first
(drug day 1) and second (drug day 2) drug testing days. Mice received IP injections of either
drug (10 mg/kg or 30 mg/kg) or vehicle 30 min before access to alcohol and water.
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Table Legend
Table 1. Mean (±SEM) time (sec/min) spent on the alcohol-paired (CS+) floor (sec/min) in each
LY2183240 dose group during the first and last 30 min of the pre-test and post-tests.

